Vascular Imaging

What Is the ACR-Recommended First Imaging Study for Suspected Large-Vessel Vasculitis?

·
What Is the ACR-Recommended First Imaging Study for Suspected Large-Vessel Vasculitis?

A 68-year-old woman presents to your clinic with three months of fatigue, unintentional weight loss, and new-onset arm claudication. Her inflammatory markers are markedly elevated, with an ESR of 92 mm/hr and a CRP of 75 mg/L. You palpate diminished brachial pulses bilaterally, and her blood pressure is asymmetric. The clinical picture strongly suggests a Large-Vessel Vasculitis (LVV), such as Giant Cell Arteritis involving the aorta and its branches. You need to confirm the diagnosis and assess the extent of disease, but which imaging study should you order first? This article provides a deep dive into the American College of Radiology (ACR) Appropriateness Criteria for this specific scenario, explaining the rationale for the recommended initial study. For this presentation, the ACR rates **MRA chest abdomen pelvis with IV contrast** as *Usually Appropriate*.

Who Fits This Clinical Scenario for Suspected Large-Vessel Vasculitis?

This guidance applies to patients where there is a new clinical suspicion of Large-Vessel Vasculitis (LVV), a group of disorders characterized by inflammation of the aorta and its primary branches. The two main types are Giant Cell Arteritis (GCA) and Takayasu Arteritis (TAK).

Inclusion criteria for this workflow include patients presenting with a combination of:

  • Constitutional symptoms: Unexplained fever, malaise, fatigue, or weight loss.
  • Elevated inflammatory markers: Significantly elevated Erythrocyte Sedimentation Rate (ESR) and/or C-Reactive Protein (CRP).
  • Signs of vascular compromise: Limb claudication, asymmetric blood pressures or pulses between limbs, new arterial bruits, or unexplained hypertension (if renal arteries are involved).
  • Relevant demographics: Age over 50 is typical for GCA, while age under 50 is characteristic of Takayasu Arteritis.

It is crucial to distinguish this scenario from others that may present similarly but require a different diagnostic approach. This workflow is not intended for patients whose symptoms are confined to the cranial arteries (e.g., new-onset headache, jaw claudication, visual changes), where temporal artery biopsy or ultrasound is often the first step. It also does not apply to patients with signs suggestive of medium-vessel disease, such as mononeuritis multiplex, testicular pain, or livedo reticularis, which would fall under the ACR criteria for suspected medium-vessel vasculitis.

What Diagnoses Are You Working Up with Initial LVV Imaging?

When ordering initial imaging for suspected LVV, you are primarily evaluating for inflammatory changes in the walls of the aorta and its major branches. The differential diagnosis is focused but includes important mimics that imaging can help distinguish.

Giant Cell Arteritis (GCA): This is the most common form of systemic vasculitis in adults over 50 in Western countries. While classically associated with cranial symptoms, GCA frequently involves the aorta and its branches (large-vessel GCA), leading to aortitis, stenosis, or aneurysms. Imaging is essential for diagnosing this extracranial involvement and determining the full disease burden.

Takayasu Arteritis (TAK): Often called “pulseless disease,” TAK is an LVV that predominantly affects women under the age of 50. It causes granulomatous inflammation of the aorta and its main branches, leading to stenosis, occlusion, and aneurysm formation. The clinical presentation can be nonspecific initially, making imaging a cornerstone of diagnosis.

Atherosclerotic Disease: Severe, diffuse atherosclerosis can sometimes mimic LVV by causing stenosis and constitutional symptoms. Imaging helps differentiate the smooth, circumferential wall thickening of vasculitis from the irregular, often calcified plaques of atherosclerosis. However, the two conditions can coexist, especially in older patients.

Infectious Aortitis: Though less common, infections from organisms like Salmonella, Staphylococcus, or Treponema pallidum (syphilis) can cause aortic wall inflammation and aneurysm (mycotic aneurysm). Imaging features like saccular aneurysms, periaortic fluid, or gas can suggest an infectious etiology, which is a critical distinction as the treatment involves antibiotics, not immunosuppression.

Why Is MRA of the Chest, Abdomen, and Pelvis with IV Contrast Usually Appropriate?

The ACR designates several modalities as *Usually Appropriate* for the initial workup of suspected LVV, but Magnetic Resonance Angiography (MRA) with intravenous contrast offers a powerful combination of diagnostic detail and safety, making it a primary recommendation.

The key advantage of MRA is its ability to directly visualize inflammation within the vessel wall without using ionizing radiation. On post-contrast sequences, active vasculitis manifests as mural thickening and enhancement, reflecting edema and increased vascularity. This capability is highly sensitive for active disease and can distinguish inflammatory stenosis from chronic, fibrotic changes. Because LVV is a systemic disease, imaging the entire aorta and its main branches from the chest through the pelvis is necessary to establish the full extent of involvement.

The lack of radiation (0 mSv) is a significant benefit, particularly in younger patients with Takayasu Arteritis who may require multiple follow-up scans over their lifetime to monitor disease activity and treatment response.

How do alternative studies compare?

  • CTA chest abdomen pelvis with IV contrast: Also rated *Usually Appropriate*, CTA is an excellent alternative. It is faster and more widely available than MRA and provides superior spatial resolution for assessing luminal stenosis and small branch vessel involvement. However, its primary drawback is the substantial radiation dose (ACR RRL ☢☢☢☢ to ☢☢☢☢☢), making it less ideal for young patients or those needing serial imaging. It is also less sensitive than MRA or PET for detecting subtle, non-stenotic mural inflammation.
  • FDG-PET/CT whole body: This modality is also *Usually Appropriate* and is highly sensitive for detecting active inflammation, which appears as increased FDG uptake in the vessel walls. It is particularly useful for assessing treatment response. However, it involves a significant radiation dose (ACR RRL ☢☢☢☢) and can be affected by confounding factors like extensive atherosclerosis, which may also show mild FDG uptake.
  • Arteriography: Rated as *May be appropriate*, conventional catheter-based arteriography is now rarely used for initial diagnosis. While it provides the highest spatial resolution for luminal assessment, it is invasive, carries procedural risks, and cannot visualize the vessel wall to assess for active inflammation.

What’s Next After MRA? Downstream Workflow

The results of the initial MRA guide the subsequent clinical pathway, from confirming a diagnosis to initiating treatment and planning follow-up.

If the MRA is positive for LVV: Findings of circumferential, enhancing wall thickening in the aorta and/or its major branches confirm the diagnosis in the appropriate clinical context. The next steps are to initiate high-dose glucocorticoids and often a steroid-sparing agent (like tocilizumab for GCA). The imaging results provide a baseline for assessing treatment response on future scans. A rheumatology consultation is essential for long-term management.

If the MRA is negative: A truly negative MRA in a patient with high clinical suspicion makes active LVV less likely. The next step is to reconsider the differential diagnosis. Could the symptoms be from severe atherosclerosis, an alternate inflammatory condition, or a non-vascular cause? If suspicion for vasculitis remains high despite negative imaging, one might consider an alternative modality like FDG-PET/CT, which may have higher sensitivity in some cases. If symptoms suggest medium-vessel involvement, the workup would pivot to the ACR variant for suspected medium-vessel vasculitis.

If the MRA is indeterminate: Ambiguous findings, such as mild wall thickening without definite enhancement, can be challenging. This is common in older patients with coexisting atherosclerosis. In this situation, FDG-PET/CT can be a valuable problem-solving tool, as significant FDG uptake would strongly favor active inflammation over chronic atherosclerotic change. A temporal artery biopsy may also be considered if there is any hint of cranial involvement.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected LVV requires careful attention to detail to avoid common diagnostic errors.

  • Ordering without contrast: A non-contrast MRA or CTA is insufficient for evaluating active vasculitis, as enhancement is the key feature of inflammation. Always specify “with IV contrast” and “for vasculitis” on the order.
  • Incomplete anatomic coverage: LVV is a systemic disease. Imaging only the chest or abdomen may miss significant disease in other territories. Ensure the study covers the aorta from the arch through the iliac bifurcation.
  • Misinterpreting atherosclerosis: Be cautious not to overcall vasculitis in patients with extensive atherosclerosis. Look for the classic smooth, circumferential thickening and enhancement that favors an inflammatory process.
  • Delaying treatment for imaging: In patients with severe, limb-threatening ischemia or signs of cranial GCA (vision loss), do not delay starting high-dose steroids while awaiting imaging. Imaging can still be positive in the first few days after steroid initiation.

If the clinical picture is complex or imaging results are equivocal, escalate by consulting with both a rheumatologist and a vascular imaging radiologist to correlate findings and determine the best path forward.

Related ACR Topics and Tools

For a comprehensive understanding of imaging for vasculitides and to explore related clinical scenarios, the following resources are invaluable. They provide the framework for the recommendations discussed in this article and offer tools to help with study selection and patient communication.

Frequently Asked Questions

Why is MRA preferred over CTA if both are rated ‘Usually Appropriate’ for suspected LVV?

MRA is often preferred, especially in younger patients (e.g., with suspected Takayasu Arteritis), because it does not use ionizing radiation. This is a significant advantage for a condition that may require multiple follow-up scans over a patient’s lifetime. MRA can also be more sensitive for detecting subtle, non-stenotic vessel wall inflammation and edema. However, CTA is faster, more widely available, and provides better detail of the vessel lumen, making it an excellent alternative, particularly if MRA is contraindicated or unavailable.

Should I order a temporal artery biopsy if I’m already ordering a whole-body MRA?

It depends on the clinical presentation. If the patient has specific cranial symptoms (e.g., new headache, jaw claudication, vision changes), a temporal artery biopsy and/or ultrasound is still the standard of care for diagnosing cranial GCA and should be pursued urgently. If the presentation is purely of large-vessel disease without cranial symptoms, a positive body MRA or CTA can secure the diagnosis of LVV without needing a biopsy.

How soon after starting high-dose steroids will an MRA become negative?

Vessel wall enhancement and thickening on MRA can begin to decrease within days to weeks of starting high-dose glucocorticoids. However, imaging often remains positive for some time. For this reason, if LVV is suspected, it is best to perform the diagnostic imaging as soon as possible. Do not delay life- or organ-saving steroid treatment to wait for an imaging slot; the study will likely still be diagnostic if performed within the first week of therapy.

Is a non-contrast MRA useful for this scenario?

No, a non-contrast MRA is rated as ‘May be appropriate’ but is generally insufficient for the initial diagnosis of active vasculitis. The key imaging finding of active inflammation is enhancement of the vessel wall after the administration of gadolinium-based contrast. A non-contrast study can show wall thickening but cannot differentiate active inflammation from chronic, fibrotic changes. It should only be considered if the patient has a severe contraindication to IV contrast.

What if my patient has renal insufficiency and cannot receive gadolinium contrast for an MRA?

In patients with severe renal dysfunction precluding the use of gadolinium, CTA with iodinated contrast may be an option if the benefits outweigh the risks of contrast-induced nephropathy. The best alternative, however, is often FDG-PET/CT. It does not require iodinated or gadolinium-based contrast and is highly sensitive for detecting active vascular inflammation, making it an excellent choice in this specific clinical situation.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026